Menu Search
Equities

Avalo Therapeutics Inc

C6K0:DEU

Avalo Therapeutics Inc

Actions
  • Price (EUR)12.10
  • Today's Change0.00 / 0.00%
  • Shares traded44.00
  • 1 Year change-39.26%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.

  • Revenue in USD (TTM)820.00k
  • Net income in USD-8.14m
  • Incorporated2011
  • Employees19.00
  • Location
    Avalo Therapeutics Inc540 Gaither Road, Suite 400ROCKVILLE 20850United StatesUSA
  • Phone+1 (410) 522-8707
  • Fax+1 (302) 636-5454
  • Websitehttps://www.avalotx.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		AVTX:NAQ since
announced		Transaction
value
AlmataBio IncDeal completed27 Mar 202427 Mar 2024Deal completed177.92%20.92m
Data delayed at least 15 minutes, as of Nov 13 2024 18:39 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.